Lilly Prasugrel Review Extended: Why No News May Be Good News
This article was originally published in The Pink Sheet Daily
Executive Summary
Platelet drug deadline slips, but analysis by The RPM Report suggests that may be a sign of a positive outcome.
You may also be interested in...
Cancer, Bleeding Risks At The Heart Of Prasugrel Review; Could Limiting Use Help?
FDA discusses labeling to restrict prasugrel use to one week or one month; less frequent dosing regimen would dampen sales projections.
Cancer, Bleeding Risks At The Heart Of Prasugrel Review; Could Limiting Use Help?
FDA discusses labeling to restrict prasugrel use to one week or one month; less frequent dosing regimen would dampen sales projections.
Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3
Firm reports ’08 net loss from ImClone deal and Zyprexa settlement